Balance Disorders News and Research

RSS

A balance disorder is a disturbance that causes an individual to feel unsteady, giddy, woozy, or have a sensation of movement, spinning, or floating. An organ in our inner ear, the labyrinth, is an important part of our vestibular (balance) system. The labyrinth interacts with other systems in the body, such as the visual (eyes) and skeletal (bones and joints) systems, to maintain the body's position. These systems, along with the brain and the nervous system, can be the source of balance problems.

EU funds ‘Keep Control’ project that focuses on balance and gait deficits in older adults

Balance problems when standing and walking are ubiquitous in the older population, and can lead to a significant burden for the individual and society.

31 May 2017

IU researchers develop new method to grow inner ear tissue from human stem cells

Researchers at Indiana University School of Medicine have successfully developed a method to grow inner ear tissue from human stem cells-; PhDa finding that could lead to new platforms to model disease and new therapies for the treatment of hearing and balance disorders.

3 May 2017

First-ever clinical study shows that older adults benefit from hearing aid use

The first-ever placebo-controlled, double-blind, randomized clinical trial of hearing aid outcomes published today in the American Journal of Audiology shows that older adults benefit from hearing aid use.

2 Mar 2017

Sighted people can be trained to use echolocation to estimate sizes of enclosed spaces

Humans can be trained to use echolocation to estimate the sizes of enclosed spaces. Ludwig-Maximilians-Universitaet in Munich researchers now show that the learning process involves close coordination between sensory and motor cortex.

28 Jan 2017

Research highlights how the brain handles numbers

Small numbers are processed in the right side of the brain, while large numbers are processed in the left side of the brain, new research suggests.

4 Mar 2016

Nearly 3.3 million children in U.S. have dizziness or balance problem

More than 1 in 20 (nearly 3.3 million) children between the ages of 3 and 17 have a dizziness or balance problem, according to an analysis of the first large-scale, nationally representative survey of these problems in U.S. children.

28 Jan 2016

CRISPR tool unlocks potential for novel treatments across different therapeutic areas

CRISPR is one of the most exciting advances in gene-based medicine in decades. A uniquely powerful tool for editing the genome, it allows scientists to manipulate DNA with unprecedented precision by deleting unwanted or faulty genes and replacing them with different ones. Its promise in this field of medicine is immense, unlocking the potential for novel treatments across a wide range of therapeutic areas.

22 Nov 2015

Scientists use new technology to create gene expression map of inner ear cell development

Using a sensitive new technology called single-cell RNA-seq on cells from mice, scientists have created the first high-resolution gene expression map of the newborn mouse inner ear.

16 Oct 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

GenVec reports net loss of $1.9 million for second quarter 2015

GenVec, Inc. today reported financial results for the second quarter ended June 30, 2015. For the three months ended June 30, 2015, GenVec reported a net loss of $1.9 million, or $0.11 per share, on revenues of $0.1 million, compared with a net loss of $1.7 million, or $0.10 per share, on revenues of $0.1 million, for the same period in the prior year.

7 Aug 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

$Brittle bones does not significantly affect occurrence of bone fractures among older people$

Brittle bones does not significantly affect occurrence of bone fractures among older people

Anti-osteoporotic medication is not an effective means for preventing hip fractures among the elderly, concludes a study recently published in the BMJ. According to Professor Teppo Järvinen from the University of Helsinki, who heads the research group, the prevalent assumption that brittle bones cause hip fractures is fundamentally flawed.

27 May 2015

GenVec reports net loss of $1.5 million for first quarter 2015

GenVec, Inc. today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year.

8 May 2015

GenVec, Laboratory of Malaria Immunology and Vaccinology sign research collaboration agreement

GenVec, Inc. today announced that it has signed a research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

21 Apr 2015

GenVec reports record financial results for Q4 and fiscal year 2014

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014. For the year ended December 31, 2014, the company reported a net loss of $2.5 million, or $0.16 per share, compared with a net loss of $10.0 million, or $0.77 per share, for the year ended December 31, 2013.

24 Mar 2015

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

GenVec, Inc. today announced that it has formed a collaboration with TheraBiologics to develop cancer therapeutics leveraging both GenVec's proprietary gene delivery platform and TheraBiologics' proprietary neural stem cell (NSC) technology.

23 Mar 2015

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.

9 Dec 2014

Researchers create new vestibular test to add to comprehensive concussion evaluation

Researchers at UPMC and the University of Pittsburgh have created a new, 5- to 10-minute test that could be added to a clinician's concussion evaluation toolkit for a more comprehensive assessment of the injury.

11 Sep 2014

GenVec reports net loss of $1.7 million for second quarter 2014

GenVec, Inc. today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year.

12 Aug 2014